First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer. Yeh R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, et al. J Nucl Med 2024 Jan 25:jnumed.123.266392. doi: 10.2967/jnumed.123.266392.

Read + Share

Amedeo Smart

Independent Medical Education

Yeh R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, et al. First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer. J Nucl Med 2024 Jan 25:jnumed.123.266392. doi: 10.2967/jnumed.123.266392.
PMID: 38272704